Lung AI vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung AI

by Exo

EchoNext

by Pathway Labs

AI Verdict

Tool A (Lung AI) is an AI-powered handheld ultrasound for real-time cardiac and lung imaging, ideal for immediate point-of-care diagnostics. Tool B (EchoNext) analyzes standard ECGs to detect hidden structural heart disease, serving as a non-invasive diagnostic support tool for broader clinical use. While both focus on cardiology and AI-driven diagnostics, their distinct methodologies – ultrasound imaging versus ECG analysis – make them complementary rather than direct competitors.

Choose Lung AI if…

Choose Lung AI if you need real-time, point-of-care diagnostic support for cardiac and lung conditions using a handheld ultrasound device. This tool is ideal for emergency medicine or critical care settings where rapid assessment of conditions like pleural effusion, consolidation/atelectasis, or heart failure (e.g., LVEF measurement) is crucial, even for users with varying levels of ultrasound expertise.

View Lung AI →

Choose EchoNext if…

Choose EchoNext if you need a non-invasive, AI-powered screening tool to detect hidden structural heart disease from standard ECGs. This is particularly useful for broad patient populations in primary care, family medicine, or hospital medicine to identify individuals at risk for conditions like heart failure, valve disease, or pulmonary hypertension who may warrant further cardiac ultrasound evaluation.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung AI	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-device (integrated with Exo Iris handheld ultrasound device)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool A (Lung AI) is integrated directly with a handheld ultrasound device (Exo Iris) and features on-device AI processing, allowing it to operate without an internet connection. It also includes 'Guided image capture' and 'SweepAI' for real-time feedback and image quality monitoring, which simplifies the process for users of varying experience levels.

Clinical Value

Lung AI

Both tools offer significant clinical value. However, Tool A (Lung AI) provides real-time AI-powered detection of multiple conditions (pleural effusion, consolidation/atelectasis, cardiac conditions like heart failure and hypertrophy) directly at the point of care, aiding immediate decision-making. Tool B (EchoNext) analyzes ECGs to detect hidden structural heart disease, which is valuable for screening and identifying patients who need further imaging, but it's a step removed from real-time, point-of-care diagnosis.

Pricing & Value

EchoNext

Tool B (EchoNext) offers transparent tiered pricing starting at $600/month, with details on implementation fees and discounts. Tool A (Lung AI) states 'contact for pricing' with no further details, making it difficult to assess its value proposition without direct inquiry.

Enterprise Readiness

Tie

Both tools demonstrate enterprise readiness. Tool A (Lung AI) is designed for integration with existing hospital systems (DICOM, PACS, VNA, worklist integration) and offers secure cloud storage. Tool B (EchoNext) is available through the OpenEvidence clinical decision support platform, which is used by a large number of physicians, and Pathway Labs is actively expanding across health systems.

Innovation

Lung AI

Tool A (Lung AI) demonstrates higher innovation by integrating AI directly into a handheld ultrasound device for real-time, on-device processing without internet, and offering features like SweepAI for image quality. This brings advanced diagnostic capabilities to the point of care in a highly portable and accessible format. Tool B (EchoNext) is innovative in its ability to detect structural heart disease from standard ECGs, a novel application, but its deployment is through an existing platform.

Support & Docs

Tie

Both tools mention aspects of support and documentation. Tool A (Lung AI) highlights 'Exo U (AI-powered POCUS education and training)' which suggests strong educational resources. Tool B (EchoNext) is deployed through the OpenEvidence platform, implying that support and documentation would be available through that established system. Without more specific details on the breadth and depth of support and documentation for each, it's difficult to declare a definitive winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung AI	EchoNext
Tool Name	Lung AI	EchoNext
Company	Exo	Pathway Labs
Tagline	Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning.	How's your heart?
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Emergency Medicine, Pulmonology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features (Lung/Cardiac)	AI-powered detection of pleural effusion, AI-powered detection of consolidation/atelectasis, Automated AI-based indicators for cardiac conditions (e.g., heart failure, hypertrophy)	Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators

Videos

Demos, reviews, and walkthroughs featuring Lung AI and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Lung AI is integrated directly into the Exo Iris handheld ultrasound device, processing AI on-device without needing an internet connection, which streamlines point-of-care imaging workflows. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, aiming to embed its screening outputs directly into tools physicians already use during patient visits, rather than requiring a separate workflow.

What is the accuracy and sensitivity of each tool in detecting relevant conditions?

Exo Lung AI has demonstrated high accuracy, with a sensitivity of 96.7% and specificity of 91.2% for pleural effusion detection, and 96.8% sensitivity and 94.5% specificity for consolidation/atelectasis. It has shown to improve diagnostic performance for clinicians, especially less experienced users. EchoNext has shown high accuracy in detecting structural heart disease, with an AUROC of 85.2% in internal tests and 78-80% in external validation. In a study, EchoNext correctly identified 77% of structural heart problems from ECGs alone, compared to 64% for cardiologists.

What is the learning curve for physicians to effectively use each tool?

Exo Lung AI is designed to simplify the process of obtaining and interpreting images, with features like SweepAI for real-time image quality monitoring and guided image capture, making it beneficial for both early POCUS users and seasoned experts. Studies have shown that novice operators achieved diagnostic-quality images after one day of AI-guided training with similar handheld ultrasound devices. EchoNext analyzes standard ECGs, which are routine tests, and its integration with OpenEvidence aims to make it accessible within existing physician tools, potentially reducing a steep learning curve for interpretation.

What kind of clinical support and training are available for these tools?

Exo offers POCUS education and training, including on-demand educational resources and coached training, to support adoption and competency in point-of-care ultrasound. EchoNext's integration with the OpenEvidence platform suggests that support would be available through that platform, which is designed for clinical decision support.

How quickly can a practice expect to see value from implementing these tools?

Exo Lung AI provides real-time feedback and on-device AI processing, allowing for immediate answers at the point of care and accelerating diagnosis and treatment pathways. EchoNext aims to provide early detection of structural heart disease from routine ECGs, potentially leading to earlier interventions and improved patient outcomes, thus offering value by identifying at-risk patients who might otherwise be missed.

What audit-trail features are available to track AI-assisted diagnoses and physician overrides?

The provided information does not explicitly detail specific audit-trail features for either Lung AI or EchoNext. However, Exo's focus on workflow deployment and operations, including documentation automation and QA workflows, suggests a framework for tracking usage. For EchoNext, its role as a screening tool that flags patients for further evaluation implies that the physician's subsequent diagnostic decisions and actions would be documented within the existing EHR system.

Are there customer references or case studies available to demonstrate real-world impact, especially for multi-site rollouts?

Exo's AI has been developed and tested using over 100,000 scans from various patient populations and diagnostic types, with validation from diverse demographics. EchoNext was trained on over 700,000 paired ECG and echocardiogram records across the NewYork-Presbyterian health system and has been validated across more than 20 hospitals and 500,000 patients in the U.S. and Canada. A prospective trial and a silent deployment study have also been conducted for EchoNext.